Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Provided By GlobeNewswire
Last update: Mar 11, 2025
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -
Read more at globenewswire.com
